Citations

Showing 10 of 108104 citations.

Utility of Antinuclear Antibody Screening by Various Methods in a Clinical Laboratory Patient Cohort
Deng, Xiaoli , Peters, Brian E., Ettore, Michael, Ashworth, Judy, Brunelle, Lynn A, Crowson, Cynthia S. , Moder, Kevin G., Snyder, Melissa R. , Peters, Brian, Ettore, Michael W, Ashworth, Judy

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 1 | Issue: 1 | Pages: 36-46

10.1373/jalm.2016.020172 | PMID 33626797 Get It

Abstract Background Antinuclear antibody (ANA)5 testing is routinely performed during evaluation of patients with a suspected connective tissue disease (CTD), yet the question of which method is most appropriate remains controversial. The purpose of this study was to evaluate the clinical utility of ANA testing by an enzyme immunoassay (EIA), an immunofluorescence assay (IFA), and a multiplex immunoassay (MIA) in a routine laboratory population. Methods Samples (n = 1000) were collected from specimens submitted for ANA testing by EIA (Bio-Rad). All samples were subsequently analyzed by IFA (Zeus) and MIA (Bio-Rad). The sample cohort was weighted to represent the routine testing population. Diagnostic information was obtained by chart review. Results For the diagnosis of a CTD, ROC curve analysis demonstrated no significant differences between IFA (area under the curve 0.81) and EIA (0.84) (P = 0.25), with overlay of a single point for the MIA. When normalized to a specificity of approximately 90%, the sensitivities of the MIA, EIA, and IFA were 67%, 67%, and 56%, respectively. By varying the clinical cutoff, the IFA could achieve the highest sensitivity of 94%; however, the corresponding specificity was only 43%. In contrast, a strongly positive EIA had a specificity of 97%, although, at this cutoff, the sensitivity was only 40%. Conclusions Although the overall diagnostic performance of the IFA, EIA, and MIA were not statistically different, the clinical sensitivity and specificity varied dramatically based on the positive/negative cutoff. Knowledge about the performance characteristics of each method will significantly aid in the interpretation of ANA testing.
Denise Louis-Bar
Koehler, Peter J. , Boes, Christopher J. , Coon, Elizabeth A.

Mayo Clinic

Neurology | July 23, 2018 | Volume: 91 | Issue: 4 | Pages: 175-179

10.1212/wnl.0000000000005866 | PMID 30037912 Get It

Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline—Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients
Jannetto, Paul J. , Bratanow, Nancy C, Clark, William , Hamill-Ruth, Robin J. , Hammett‐Stabler, Catherine A. , Kassed, Cheryl A., McMillin, Gwendolyn A. , Melanson, Stacy E.F. , Langman, Loralie J., Clark, William A, Huestis, Marilyn Ann

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 4 | Pages: 489-526

10.1373/jalm.2017.023341 | PMID 33636890 Get It

Proenkephalin (PENK) as a Novel Biomarker for Kidney Function
Struck, Joachim , Wu, Alan H.B. , Zarbock, Alexander , Somma, Salvatore Di , Mehta, Ravindra L. , Nadim, Mitra K. , Maisel, Alan S. , Neath, Sean‐Xavier , Jaffe, Allan S. , Pickkers, Peter , Jaffe, Allan, Mehta, Ravindra L , Beunders, Remi , Koyner, Jay L. , Murray, Patrick T. , Jaffe, Allan S.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 3 | Pages: 400-412

10.1373/jalm.2017.023598 | PMID 33636859 Get It

Abstract Background The assessment of kidney function and detection of acute kidney injury (AKI) remain cumbersome. On the one hand, because of limited accuracy of established tests: The most widely used methods are creatinine based, which lack in sensitivity, as creatinine is not purely filtrated by the kidney and rises relatively late after onset of AKI. On the other hand, because of labor-intensiveness: Gold standard inulin clearance and comparable methods involve intravenous compound infusion, blood sampling at several time points, and have error-sensitive determination methods. In recent years, several biomarkers have been put forward (e.g., NGAL, KIM-1, TIMP-2*IGFBP-7), but clinical implementation is limited up to now. Content Proenkephalin (PENK) represents a new candidate to determine kidney function. This peptide is cleaved from the precursor peptide preproenkephalin A alongside enkephalins (endogenous opioids) and is filtrated in the glomerulus. PENK plasma concentration appears to accurately represent glomerular filtration rate in patients diagnosed with sepsis or cardiac diseases. Moreover, increased PENK concentration is found to be associated with longer-term outcome concerning AKI and cardiac diseases. Lastly, the predominant receptor of enkephalins, the δ-opioid receptor, is expressed with the highest density in the kidney, suggesting that enkephalins could also exert a direct effect on kidney function. Summary In this review, we present an overview of enkephalins and the assessment of kidney function using this possible new functional biomarker PENK and compare it with established and novel biomarkers.
Proton therapy patterns of care among pediatric and adult patients with CNS tumors
Hartsell, William F. , Badiyan, Shahed N. , Wang, Chiachien J., Rossi, Carl J., Kotecha, Rupesh , Vora, Sujay A., Vargas, Carlos , Larson, Gary, Halasz, Lia M. , Vora, Sujay, Tseng, Yolanda D. , Tsai, Henry K.

Mayo Clinic

Neuro-Oncology | July 23, 2018 | Volume: 20 | Issue: 11 | Pages: 1556-1557

10.1093/neuonc/noy116 | PMID 30085163 Get It

A population of gut epithelial enterochromaffin cells is mechanosensitive and requires Piezo2 to convert force into serotonin release
Alcaino, Constanza , Knutson, Kaitlyn R. , Treichel, Anthony J. , Yildiz, Gulcan , Strege, Peter R. , Li, Joyce H. , Leiter, Andrew B. , Szurszewski, Joseph H., Farrugia, Gianrico , Li, Joyce H , Farrugia, Gianrico , Beyder, Arthur , Treichel, Anthony J , Strege, Peter R , Linden, David R. , Beyder, Arthur

Mayo Clinic

Proceedings of the National Academy of Sciences | July 23, 2018 | Volume: 115 | Issue: 32 | Pages: No page available

10.1073/pnas.1804938115 | PMID 30037999 Get It

Significance Mechanical forces are important for normal gastrointestinal tract function. The enterochromaffin cells in the gastrointestinal epithelium have been proposed, but not previously shown, to be specialized sensors that convert forces into serotonin release, and serotonin released from these cells is important for normal gastrointestinal secretion and motility. The findings in this study show that some enterochromaffin cells are indeed mechanosensitive, and that they use mechanosensitive Piezo2 channels to generate an ionic current that is critical for the intracellular Ca 2+ increase, serotonin release, and epithelial fluid secretion.
CDKN2AGermline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations
Wieben, Eric D. , Chaffee, Kari G. , Antwi, Samuel O. , Olopade, Olufunmilayo I. , Li, Donghui , Highsmith, W. Edward, Colón‐Otero, Gerardo , Khanna, Lauren , Frucht, Harold, Blot, William J. , Wu, Lang , Almada, Luciana L. , Fernández-Zapico, Martín E. , Sicotte, Hugues , Pedersen, Katrina S. , Petersen, Gloria M. , Rabe, Kari G. , McWilliams, Robert R. , Raskin, Leon , Li, Donghui , Permuth, Jennifer B , Sicotte, Hugues , Antwi, Samuel O , Olopade, Olufunmilayo I , Pedersen, Katrina , Permuth, Jennifer B. , Olson, Janet E. , Genkinger, Jeanine M. , Zheng, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 23, 2018 | Volume: 27 | Issue: 11 | Pages: 1364-1370

10.1158/1055-9965.epi-17-1065 | PMID 30038052 Get It

AbstractBackground: Pathogenic germline mutations in the CDKN2A tumor suppressor gene are rare and associated with highly penetrant familial melanoma and pancreatic cancer in non-Hispanic whites (NHW). To date, the prevalence and impact of CDKN2A rare coding variants (RCV) in racial minority groups remain poorly characterized. We examined the role of CDKN2A RCVs on the risk of pancreatic cancer among minority subjects.Methods: We sequenced CDKN2A in 220 African American (AA) pancreatic cancer cases, 900 noncancer AA controls, and 183 Nigerian controls. RCV frequencies were determined for each group and compared with that of 1,537 NHW patients with pancreatic cancer. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for both a case–case comparison of RCV frequencies in AAs versus NHWs, and case–control comparison between AA cases versus noncancer AA controls plus Nigerian controls. Smaller sets of Hispanic and Native American cases and controls also were sequenced.Results: One novel missense RCV and one novel frameshift RCV were found among AA patients: 400G>A and 258_278del. RCV carrier status was associated with increased risk of pancreatic cancer among AA cases (11/220; OR, 3.3; 95% CI, 1.5–7.1; P = 0.004) compared with AA and Nigerian controls (17/1,083). Further, AA cases had higher frequency of RCVs: 5.0% (OR, 13.4; 95% CI, 4.9–36.7; P < 0.001) compared with NHW cases (0.4%).Conclusions: CDKN2A RCVs are more common in AA than in NHW patients with pancreatic cancer and associated with moderately increased pancreatic cancer risk among AAs.Impact: RCVs in CDKN2A are frequent in AAs and are associated with risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 27(11); 1364–70. ©2018 AACR.
Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance)
Blarigan, Erin L. Van , Ou, Fang‐Shu , Niedzwiecki, Donna , Zhang, Sui , Fuchs, Charles S. , Ogino, Shuji , Benson, A.B., Hantel, Alexander, Atkins, James N., Giovannucci, Edward L. , Meyerhardt, Jeffrey A. , Saltz, Leonard , Ogino, Shuji , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Saltz, Leonard B. , Mayer, Robert J. , Venook, Alan P. , Song, Mingyang

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 23, 2018 | Volume: 27 | Issue: 10 | Pages: 1227-1230

10.1158/1055-9965.epi-18-0487 | PMID 30038051 Get It

Abstract Background: Higher intake of long-chain ω-3 polyunsaturated fatty acids and nuts, rich plant sources of unsaturated fats, after colon cancer diagnosis are associated with improved survival. It is not known whether the amount or the distribution of other types of fat is associated with survival after colon cancer. Methods: We prospectively examined postdiagnostic total, animal, and vegetable fats, as well as the saturated, monounsaturated, polyunsaturated, and trans fat in relation to disease-free survival among 1,011 patients with stage III colon cancer. Patients were enrolled between 1999 and 2001 at the onset of adjuvant chemotherapy and followed for recurrence or death through 2009. Results: During median follow-up of 7 years, we observed 305 deaths and 81 recurrences (total events: 386). Neither total nor any specific type of dietary fat examined was statistically significantly associated with risk of cancer recurrence or death from any cause (disease-free survival) after stage III colon cancer. Conclusions: The amount and type (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer does not appear to be substantially associated with risk of recurrence or survival. Impact: Neither total nor major types (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer was associated with cancer recurrence or survival. Cancer Epidemiol Biomarkers Prev; 27(10); 1227–30. ©2018 AACR.
Application of multi-state models in cancer clinical trials
Le‐Rademacher, Jennifer , Peterson, Ryan , Therneau, Terry M. , Sanford, Ben L. , Stone, Richard M. , Mandrekar, Sumithra J. , Le-Rademacher, Jennifer G , Peterson, Ryan A

Mayo Clinic

Clinical Trials | July 23, 2018 | Volume: 15 | Issue: 5 | Pages: 489-498

10.1177/1740774518789098 | PMID 30035644 Get It

Background/aims The goal of this article is to illustrate the utility of multi-state models in cancer clinical trials. Our specific aims are to describe multi-state models and how they differ from standard survival methods, to illustrate how multi-state models can facilitate deeper understanding of the treatment effect on multiple paths along the disease process that patients could experience in cancer clinical trials, to explain the differences between multi-state models and time-dependent Cox models, and to briefly describe available software to conduct such analyses. Methods Data from 717 newly diagnosed acute myeloid leukemia patients who enrolled in the CALGB 10603 trial were used as an illustrative example. The current probability-in-state was estimated using the Aalen–Johansen estimator. The restricted mean time in state was calculated as the area under the probability-in-state curves. Cox-type regression was used to evaluate the effect of midostaurin on the various clinical paths. Simulation was conducted using a newly constructed shiny application. All analyses were performed using the R software. Results Multi-state model analyses of CALGB 10603 suggested that the overall improvement in survival with midostaurin seen in the primary analysis possibly resulted from a higher complete remission rate in combination with a lower risk of relapse and of death after complete remission in patients treated with midostaurin. Simulation results, in a three-state illness-death without recovery model, demonstrate that multi-state models and time-dependent Cox models evaluate treatment effects from different frameworks. Conclusion Multi-state models allow detailed evaluation of treatment effects in complex clinical trial settings where patients can experience multiple paths between study enrollment and the final outcome. Multi-state models can be used as a complementary tool to standard survival analyses to provide deeper insights to the effects of treatment in trial settings with complex disease process.
Cognitive outcomes after critical illness
Sakusic, Amra , Rabinstein, Alejandro A.

Mayo Clinic

Current Opinion in Critical Care | July 23, 2018 | Volume: 24 | Issue: 5 | Pages: 410-414

10.1097/mcc.0000000000000527 | PMID 30036191 Get It

Purpose of review There is an increasing realization in the critical care community that persistent cognitive impairment is a common and disabling complication after ICU care. In this review, we discuss the best available information on the magnitude of the problem, its possible mechanisms, risk factors, management strategies and prognosis. Recent findings Estimates of the incidence of persistent cognitive impairment after critical illness vary widely across studies but the most solid prospective information indicates that it may occur in 20–40% of patients discharged from the ICU. From the available evidence, it is difficult to discriminate between de novo cognitive impairment and exacerbation of preexistent cognitive decline. The pathogenesis is multifactorial but inflammatory mechanisms causing derangements of endothelial function and blood–brain barrier integrity might play an important role. Brain atrophy and white matter tract disruption can be structural correlates of the cognitive decline. Prolonged delirium in the ICU is the strongest risk factor for the development of subsequent persistent cognitive impairment. Management strategies are currently limited to those designed to prevent and improve delirium. Cognitive trajectories may vary but a substantial proportion of patients with cognitive impairment 3 months after ICU discharge are still cognitively impaired at 12 months. Summary Persistent cognitive impairment is a major complication of critical illness. Our knowledge of this problem remains incomplete. Collaborative research is indispensable to improve our understanding of this disabling sequel and to identify ways to prevent it.